Brief: FDA Grants Rare Pediatric Disease Designation To NS-050/NCNP-03 For Treatment Of Duchenne Muscular Dystrophy
10/09/2024 20:56
Sept 10 (Reuters) - NS Pharma Inc:
* FDA GRANTS RARE PEDIATRIC DISEASE DESIGNATION TO
NS-050/NCNP-03
FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Source text for Eikon: ID:nPn8kLbqXa
Further company coverage: 4516.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nippon Shinyaku
See all newsTable: Nippon Shinyaku -Q1 group results (IFRS)
Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -2025/26 group results (IFRS)
Table: Nippon Shinyaku -2025/26 parent results
Table: Nippon Shinyaku -9-MTH group results (IFRS)